Poster to highlight lead therapeutic candidates, a series of fully personalized T cell therapies
WATERTOWN, Mass.–(BUSINESS WIRE)–RootPath, a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude, today announced that a poster presentation highlighting its lead therapeutic candidates, a series of fully personalized T cell therapies, at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting taking place May 16-19, 2022 in Washington, D.C.
The details of the poster presentation are as follows:
Abstract Title: Massively Parallel TCR Gene Synthesis and Unbiased Functional Screening: From Decoding Immune Interactome to Fully Personalized TCR-T Therapy
Author: Zi Chen
Date: May 17, 2022 at 5:30PM EDT
Final abstract number: 2022-A-1954-ASGCT
About RootPath
RootPath is a synthetic biology company that elevates the throughput of gene function interrogation by orders of magnitude. Our Molecular Programming-based DNA fragment assembly technology gives researchers and drug developers unprecedented, equitable access to long synthetic genes and their functional readouts. By applying our technology to mine a patient’s immunome, we create truly personalized T cell therapies for solid tumors. Together, with leading partners, we are exploring new applications across multiple industries. We enable biology at scale.
Contacts
Michael Falcone
MacDougall Advisors
781-235-3060
mfalcone@macdougall.bio
